Analysts Anticipate Leap Therapeutics Inc (LPTX) to Post ($0.77) Earnings Per Share

Shares of Leap Therapeutics Inc (NASDAQ:LPTX) have received an average broker rating score of 1.50 (Buy) from the two brokers that cover the company, Zacks Investment Research reports. One analyst has rated the stock with a buy recommendation and one has issued a strong buy recommendation on the company.

Analysts have set a twelve-month consensus target price of $15.50 for the company and are forecasting that the company will post ($0.77) EPS for the current quarter, according to Zacks. Zacks has also given Leap Therapeutics an industry rank of 190 out of 265 based on the ratings given to related companies.

Separately, Zacks Investment Research raised Leap Therapeutics from a “hold” rating to a “buy” rating and set a $7.00 price target for the company in a report on Tuesday, January 23rd.

In other news, COO Augustine Lawlor bought 1,057,769 shares of the firm’s stock in a transaction that occurred on Tuesday, November 14th. The shares were bought at an average cost of $6.09 per share, for a total transaction of $6,441,813.21. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. 58.40% of the stock is currently owned by insiders.

Shares of Leap Therapeutics (NASDAQ LPTX) traded up $0.01 during trading hours on Tuesday, reaching $6.33. The company’s stock had a trading volume of 52,378 shares, compared to its average volume of 70,238. Leap Therapeutics has a 1-year low of $4.90 and a 1-year high of $9.44.

Leap Therapeutics (NASDAQ:LPTX) last posted its quarterly earnings results on Monday, November 13th. The company reported ($0.73) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.62) by ($0.11). equities research analysts forecast that Leap Therapeutics will post -3.63 EPS for the current fiscal year.

COPYRIGHT VIOLATION WARNING: This piece of content was published by American Banking News and is owned by of American Banking News. If you are viewing this piece of content on another domain, it was stolen and republished in violation of U.S. & international trademark and copyright legislation. The original version of this piece of content can be accessed at

About Leap Therapeutics

Leap Therapeutics, Inc, formerly HealthCare Pharmaceuticals, Inc, is a clinical-stage biopharmaceutical company. The Company engages in acquiring and developing therapeutics in cancer biology. Its lead product candidates for use in clinical trials include TRX518 and DKN-01. DKN-01 is a monoclonal antibody targeting Dickkopf-related protein 1 (DKK1).

Get a free copy of the Zacks research report on Leap Therapeutics (LPTX)

For more information about research offerings from Zacks Investment Research, visit

Receive News & Ratings for Leap Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Leap Therapeutics and related companies with's FREE daily email newsletter.

Leave a Reply